Will Cochrane retract their Review of Exercise Therapy for ME/CFS or publish an updated review (against GET) by 2029?
Health & MedicineOne-Off2a
Manifold MarketsSin KYCDatos de resolución verificadosCalibración aceptablePronóstico comunitario actual
Sí 79.5%
Pronosticadores
5
Tipo de pregunta
binary
Metodología
Play-money forecasting platform
Tipo de fuente
Pronóstico
Datos de mercado
Actualizado hace 18 horas
Desactualizado30 jun 24, 16:24 UTC31 dic 28, 22:59 UTC
Tendencias
Mercados Relacionados
Preguntas relacionadas para dar contexto, no una comparación de contratos equivalentes.
Will ME/CFS blood test replicate in larger study?
Manifold MarketsWill the finding of high WASF3 in ME/CFS (Hwang,PNAS, 2023) be successfully replicated by the end of 2027?
Manifold MarketsCommercially available tooth regeneration therapy
Manifold MarketsHantavirus pandemic in 2026?
PolymarketWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
KalshiFDA approves skin cancer vaccine by which date?
PolymarketReglas
In 2019 Cochrane published a review concluding graded exercise therapy (GET) was beneficial for people with ME/CFS.
- This goes against nearly every other major organisation, whom say that exercise therapy is harmful for people with ME/CFS:
- CDC (Since 2017) (US)
- NICE and NHS (since 2021) (UK)
- Mayo Clinic (Since 2024) (US)
- Australian ME/CFS Guidelines (Since 2024) (Australia)
Mercados abiertos
Health & MedicinePOLYMARKETHantavirus pandemic in 2026?
- No-0.2pt97%
- Yes+0.2pt3%
- Volumen total
- 15,6 M €
- Volumen 24h
- 20,3 mil €
KALSHIWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- No96%
- Yes+0.6pt4%
- Volumen total
- 1,6 M €
- Volumen 24h
- 8 mil €
POLYMARKETFDA approves skin cancer vaccine by which date?
- December 31,+4.0pt65%
- September41%
- June28%
- Volumen total
- 84,1 mil €
POLYMARKETEbola pandemic in 2026?
- No-0.1pt97%
- Yes+0.1pt3%
- Volumen total
- 652,6 mil €
- Volumen 24h
- 3,4 mil €
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 400097%
- Above 6000-4.0pt58%
+2 resultados más
- Volumen total
- 865,4 mil €
- Volumen 24h
- 3 mil €
POLYMARKETNew pandemic in 2026?
- No+1.0pt94.1%
- Yes-1.0pt5.9%
- Volumen total
- 915,2 mil €
- Volumen 24h
- 1,2 mil €
- When will the FDA approve Intellia Therapeutics' lonvo-z?
- Will 3 mg THC beverages be federally legal to sell?
- Measles cases in U.S. in 2026?
- Cyclosporiasis cases reported in the US in 2026?
- FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
- What will the average number of measles cases be during Trump's term?
- Will the FDA approve CagriSema?
- When will the FDA reclassify BPC-157 to Category 1?
- FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
- FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)
- When will Compass Pathways submit a NDA for COMP360 psilocybin?
Preguntas frecuentes
- ¿Cuáles son las probabilidades actuales de Will Cochrane retract their Review of Exercise Therapy for ME/CFS or publish an updated review (against GET) by 2029??
- Manifold Markets cotiza Yes al 80% a fecha de 8 de septiembre de 2026.
- ¿Cuándo se resuelve Will Cochrane retract their Review of Exercise Therapy for ME/CFS or publish an updated review (against GET) by 2029??
- Está previsto que Will Cochrane retract their Review of Exercise Therapy for ME/CFS or publish an updated review (against GET) by 2029? se resuelva el 31 de diciembre de 2028.
- ¿Cómo se liquida Will Cochrane retract their Review of Exercise Therapy for ME/CFS or publish an updated review (against GET) by 2029??
- Manifold Markets liquida este mercado del siguiente modo: In 2019 Cochrane published a review concluding graded exercise therapy (GET) was beneficial for people with ME/CFS.